Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesBlockade of 2-AG hydrolysis by selective monoacylglycerol lipase inhibitor JZL184 enhances retrograde endocannabinoid signaling
Journal of Pharmacology and Experimental Therapeutics, 08/10/09
Pan B et al. – These results indicate that the degradation of 2–AG by MAGL is the rate–limiting step that determines the time course of DSE/DSI and that JZL184 is a useful tool for the study of 2–AG–mediated signaling.
Related Articles
Dynamic regulation of the endocannabinoid system: implications for analgesia
Molecular Pain, 10/09/09
Relevance Score: 88%
Spinal antinociceptive effects of cyclooxygenase inhibition during inflammation: Involvement of prostaglandins and endocannabinoids
Pain, 11/02/09
Relevance Score: 87%
Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy
Epilepsia, 10/13/09
Relevance Score: 87%
Expression and Function of Endocannabinoid Receptors in the Human Adrenal Cortex
Hormone and Metabolic Research, 11/02/09
Relevance Score: 85%
Monoacyl glycerol lipase limits the duration of endocannabinoid-mediated depolarization-induced suppression of excitation in autaptic hippocampal neurons
Molecular Pharmacology, 10/08/09
Relevance Score: 84%
Today in Major Studies...keeping you current
Receive free subspecialty "5-minute updates" via email
Evaluation of Treatment Satisfaction in Children with Allergic Disease Treated with an Antihistamine: An International, Non-Interventional, Retrospective Study
Clinical Drug Investigation, 12/11/09
Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America
Sanofi-aventis, 12/10/09
Allos Therapeutics' FOLOTYN Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Lymphoma
Allos Therapeutics, 12/09/09
Sponsor
Article Search
Sponsor
Sponsor